| Human immunodeficiency virus I infection
Evotaz vs Symtuza
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Evotaz vs Symtuza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSymtuza has a higher rate of injection site reactions vs Evotaz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Symtuza but not Evotaz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Evotaz
Symtuza
At A Glance
Oral
Once daily
HIV-1 protease inhibitor with CYP3A inhibitor
Oral
Once daily
Protease inhibitor + CYP3A inhibitor + NRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet (atazanavir 300 mg/cobicistat 150 mg) orally once daily with food.
Human immunodeficiency virus I infection One tablet orally once daily with food in adults and pediatric patients weighing at least 40 kg (800 mg darunavir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide).
Contraindications
- Clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to any component
- Coadministration with strong CYP3A4 inducers
- Coadministration with drugs highly dependent on CYP3A or UGT1A1 for clearance with narrow therapeutic indices
- Coadministration with alfuzosin
- Coadministration with ranolazine
- Coadministration with dronedarone
- Coadministration with carbamazepine, phenobarbital, phenytoin
- Coadministration with colchicine in patients with hepatic or renal impairment
- Coadministration with rifampin
- Coadministration with apalutamide, encorafenib, irinotecan, ivosidenib
- Coadministration with lurasidone, pimozide
- Coadministration with dihydroergotamine, ergotamine, methylergonovine
- Coadministration with elbasvir/grazoprevir, glecaprevir/pibrentasvir
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with drospirenone/ethinyl estradiol
- Coadministration with lomitapide, lovastatin, simvastatin
- Coadministration with nevirapine
- Coadministration with sildenafil when used for pulmonary arterial hypertension
- Coadministration with indinavir
- Coadministration with triazolam, orally administered midazolam
- Alfuzosin co-administration
- Carbamazepine, phenobarbital, or phenytoin co-administration
- Colchicine in patients with renal and/or hepatic impairment
- Rifampin co-administration
- Lurasidone or pimozide co-administration
- Dronedarone, ivabradine, or ranolazine co-administration
- Ergot derivatives (dihydroergotamine, ergotamine, methylergonovine) co-administration
- St. John's wort co-administration
- Elbasvir/grazoprevir co-administration
- Lomitapide, lovastatin, or simvastatin co-administration
- Naloxegol co-administration
- Sildenafil when used for pulmonary arterial hypertension
- Orally administered midazolam or triazolam co-administration
Adverse Reactions
Most common (>=5%) Jaundice, rash
Serious Cardiac conduction abnormalities, rash, effects on serum creatinine, new onset or worsening renal impairment, chronic kidney disease, nephrolithiasis, cholelithiasis, hepatotoxicity, hyperbilirubinemia
Most common (>=2%) Diarrhea, rash, nausea, fatigue, headache, abdominal discomfort, flatulence
Serious Severe acute exacerbations of hepatitis B, hepatotoxicity, severe skin reactions, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Redistribution of body fat, rhabdomyolysis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome, crystal nephropathy, crystalluria
Pharmacology
EVOTAZ is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that prevents viral Gag and Gag-Pol polyprotein processing, and cobicistat, a CYP3A inhibitor that increases atazanavir systemic exposure.
Symtuza is a fixed-dose combination containing darunavir (an HIV-1 protease inhibitor that prevents cleavage of Gag-Pol polyproteins), cobicistat (a CYP3A inhibitor that enhances darunavir exposure), emtricitabine (an NRTI that inhibits HIV reverse transcriptase through chain termination), and tenofovir alafenamide (an NRTI prodrug converted to tenofovir diphosphate that inhibits HIV reverse transcriptase).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Evotaz
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Symtuza
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (11/12)
UnitedHealthcare
Evotaz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Symtuza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Evotaz
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Symtuza
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EvotazView full Evotaz profile
SymtuzaView full Symtuza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.